Novel Nonbiologic Therapies for Ulcerative Colitis

Juillerat, Pascal; Korzenik., JR (2014). Novel Nonbiologic Therapies for Ulcerative Colitis. In: Lichtenstein, Gary R. (ed.) Medical Therapy of Ulcerative Colitis (pp. 221-235). New York: Springer Science & Business Media 2014 10.1007/978-1-4939-1677-1_19

Text 19_Online PDF-1.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (250kB) | Request a copy

An extensive array of compounds has been studied for the treatment of ulcerative colitis (UC). The most frequently used nonbiologic drugs for the oral and intravenous treatment of ulcerative colitis include 5-aminosalicylate (5-ASA) drugs (mesalamine and derivatives), sulfasalazine, and other azo-bonded molecules of 5-ASA, steroids, calcineurin inhibitors (cyclosporine, tacrolimus, and sirolimus), thiopurines (azathioprine, 6-mercaptopurine), and methotrexate, which are already presented in other sections of this book and are thus not considered in this chapter. The therapies presented in this section should be considered as potential alternatives, mostly for mild-to-moderate ulcerative colitis (UC). They are substances mostly used without FDA indications, such as heparin, nicotine, rosiglitazone, and N-acetylcysteine as well as “natural” compounds suggested to have anti-inflammatory or reparative properties, such as aloe vera, curcumin, short-chain fatty acids, and Bowman-Birk inhibitor

Interest & Impact

Downloads

0 since deposited on 30 Mar 2015
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item